Omenn syndrome (OS) is a rare form of severe combined immunodeficiency, often characterised by an early onset of generalised erythrodermia caused by a massive infiltrate of the skin by auto-reactive T cells. We describe the case of an OS patient in which we observed a high percentage of skin-homing, circulating CD4 + and CD8 + CCR10 + T cells. Treatment of the erythrodermia with topical tacrolimus resulted in a significant clinical improvement of the skin, which was associated with normalisation of intradermal CCL27 expression. This coincided with both a reduced cutaneous T cell infiltrate as well as a specific decrease in circulating CCR10 + T cells. Thus, topical tacrolimus treatment appears to reduce CCL27 expression, thereby specifically inhibiting infiltration of skin-specific T cells.
Introduction
Omenn syndrome (OS) is an inherited immunodeficiency disorder with autoimmunelike manifestations. No or very few circulating mature B cells are found in these patients in contrast to normal or even elevated numbers of poorly functional, activated, T cells in the blood. These T cells infiltrate the skin, gut, liver and spleen resembling graft-versus-host disease 1 . Lymphocyte expression of surface adhesion and chemokine receptors is required for appropriate tissue and microenvironmental localisation. This tissue-specific homing is particularly well illustrated by the distinct mechanisms used by lymphocytes in homing to the skin 2 . Effector/memory T cells with skin-tropism are easily identified by their expression of the cutaneous lymphocyte antigen (CLA). In addition, CLA + T cells selectively express two chemokine receptors, CCR4 and CCR10, whose ligands CCL17 and CCL27 are expressed on the luminal surface of cutaneous postcapillary venules. These skin-homing T cells have clearly been shown to play a role in many inflammatory skin diseases 3 . One way to down-regulate or modulate T cell activity is by the use of immunosuppressive drugs belonging to the group of calcineurin inhibitors. Besides their primary effect, the inhibition of the synthesis of T cell growth factors, there is now also some evidence that these drugs down-modulate chemokine receptor expression, thus interfering with migration of T cells to the inflammatory site 4 . In the present study we describe a unique skin homing profile on the peripheral blood CD4 + and CD8 + T cells of an OS patient and the effect of topical tacrolimus treatment on this T cell population.
Clinical Course and Results
The patient is the second child of consanguineous parents born at term after an uncomplicated pregnancy. His five year old sister is healthy and the family history is negative for immunodeficiencies but positive for atopy. In the first week he presented with erythematous skin lesions, initially diagnosed as congenital eczema and treated 
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with topical steroids. During the first two months he developed food intolerance and low-grade enteritis. Hypo allergic formula only resulted in limited and unstable improvement. At 2.5 months he presented with rhinitis, fever (38-39ºC) and dyspnoea which improved after treatment with amoxicillin but the erythrodermia persisted and he developed generalised lymphadenopathy, conjunctivitis and otitis externa. Blood examination demonstrated a leukocytosis (27x 109/L) with a marked eosinophilia of 20-30%. An immunodeficiency was suspected and at three months the child was referred to our hospital for further evaluation. Lymphocyte subset analysis showed that virtually all CD3 + cells were T cell receptor α/β and CD45RO + and there was a lack of circulating B cells. Chimerism analysis revealed that all lymphocytes were of patient origin, excluding transferred maternal T-lymphocytes. Therefore the patient was diagnosed as severe combined immunodeficiency with an OS presentation. Genetic analysis revealed a homozygous deletion (c.591delT) in the RAG1 gene, resulting in a frame shift and a premature termination at amino acid position 20 Due to the fact that this patient, indicated as OS1, presented with a generalised skin rash, skin-homing T cells were investigated in the peripheral blood. Flow cytometric analysis revealed high percentages of both CD4 + (57.7%) and CD8 + (66.6%) T cells that expressed the skin-homing receptor CCR10, compared to the paediatric healthy donor (Figure 1 + T cells. Topical tacrolimus (Astellas Pharma Europe Ltd, Staines, UK) resulted in significant cutaneous improvement within 48h. During 7 weeks of treatment, tacrolimus blood levels between 1.9 and 12.8 ng/ml were observed, accompanied by a further reduction in erythrodermia even in non-treated skin areas. We investigated whether this treatment had an effect on peripheral blood skin-homing T cells. Figure 1 Figure 3 shows that during tacrolimus treatment, the pre-existing dense infiltrate of both CD4 + and CD8 + T cells was significantly reduced whereas the number of CD1a + Langerhans cells increased in the epidermis after treatment, in keeping with a previous report 5 . Immunohistochemical analysis also revealed that elevated expression of the CCR10 ligand, CCL27, in the epidermis of the affected skin ( Figure 3 The patient presented with erythematous skin lesions, which upon topical tacrolimus treatment resulted in significant cutaneous improvement. Informed consent from the parents was given for photograph usage. Before treatment a skin biopsy showed a markedly active lesion with prominent epidermal hyperplasia (as displayed by the haematoxylin and eosin, H&E, stain), a large infiltrate of both CD4 + (green colour depicting absence of CD8 on CD3 T cells) and CD8 + T cells (yellow due to co-localisation of CD3, green and CD8, red), a reduced epidermal expression of CD1a cells (red) and a diffuse and strong expression of CCL27 (single enzymatic staining detected by the brown colour) in the epidermis. During treatment, normal skin histology was restored with an increased number of epidermal CD1a cells, only small groups of infiltrating T cells and basal expression of CCL27. The dotted white line represents the epidermal/ dermal border.
Discussion
We have described the case of an OS patient, OS1, displaying typical OS immunological features and presenting with early onset erythrodermia. One striking feature of the peripheral blood T cells of OS1 and OS2, was the high percentage of both CD4 and CD8 T cells expressing CCR10. Although CCR10 has been clearly associated with the homing of CD4 + T cells to the skin 8;9 , few reports show any involvement on CD8 + T cells 10 . To date, studies analysing the T cell infiltrates in other skin diseases such as psoriasis and atopic dermatitis indicated that CCR10 is selectively expressed on CD4 + T cells 11;12 Tacrolimus is an immunosuppressive drug that is effective in the treatment of various skin diseases such as psoriasis and atopic dermatitis 13 . Although its inhibition of intracellular signalling pathways resulting in a lack of cytokine gene expression and T cell activation is well documented 14 , emerging evidence indicates that immunosuppressive drugs can down-modulate chemokine or chemokine receptor expression, preventing migration of T cells to the inflammatory site [15] [16] [17] . Treatment of OS1 with topical tacrolimus not only resulted in clear clinical improvement of his skin but also in a large decrease in the percentage and absolute numbers of circulating CD4 + CCR10
+ and CD8 + CCR10 + T cells. This seems to contrast with a previous report where administration of oral tacrolimus failed to control the erythrodermia in a child with OS 11 . Whilst achieving similar blood levels of tacrolimus (between 1.8 and 4.4 ng/ml in this reported case compared to between 1.9 and 12.8 ng/ml in OS1) the main difference seems to be the route of administration of tacrolimus leading to the highest concentration in the skin when topically applied. The clinical improvement in the skin and substantial decrease in skin-homing T cells in the peripheral blood of OS1 following treatment, was reflected by a clear reduction of activated T cells in the affected skin as well as a marked decrease in the expression of the CCR10 ligand, CCL27. As would be expected, treatment with tacrolimus was also associated with a reduced production of the inflammatory cytokines TNF-α and IL-2 by peripheral blood T cells. Therefore, reduction in dermal T cell numbers could be explained by several observations from OS1. Firstly, TNF-α is known to stimulate the production of CCL27 by keratinocytes 15, 16 . Thus, the reduction of TNF-α expression may have caused the decline of CCL27 expression in the skin leading to a subsequently diminished recruitment of T cells. It is also possible, that tacrolimus has a direct effect on CCR10 expression by T cells, as has been shown for other immunosuppressive drugs. However due to limited patient material we were unable to test this. In summary, our findings illustrate that topical treatment with tacrolimus has the potential to reduce a CD4/CD8 T cell mediated skin inflammatory process by a mechanism which involves down-regulation of skin specific chemokines and chemokine receptors.
